β-Endorphin levels in peripheral blood mononuclear cells and long-term naltrexone treatment in autistic children

European Neuropsychopharmacology

Volumn 9, Issue 4, 1999, Pages 361-366

  Guareschi Cazzullo, Adriana ^a   Musetti, Maria Cristina ^a   Musetti, Laura ^a   Bajo, Sonia ^a   Sacerdote, Paola ^a   Panerai, Alberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Endorphin; Autism; Behavioural improvement; Naltrexone

Indexed keywords

BETA ENDORPHIN; NALTREXONE;

BEHAVIOR; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EDITORIAL; FEMALE; HUMAN; INFANTILE AUTISM; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; SPEECH; STEREOTYPY;

AUTISTIC DISORDER; BETA-ENDORPHIN; CHILD; CHILD, PRESCHOOL; COGNITION; HUMANS; LEUKOCYTES, MONONUCLEAR; NALTREXONE; NARCOTIC ANTAGONISTS; STEREOTYPED BEHAVIOR;

EID: 0033153241     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(99)00010-3     Document Type: Editorial

References (47)

1. Adrien J.L., Barthelemy C., Perrot A., Roux S., Lenoir P., Hameury L., Sauvage D. Validity and reliability of the Infant Behaviour Summarized Evaluation (IBSE): A rating scale for the assessment of young children with autism and developmental disorders. J. Aut. Dev. Disorders. 22:1992;123-130.
2. American Psychiatry Association . Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition :1994;APA, Washington, DC. It.: Manuale Diagnostico e Statistico dei Disturbi Mentali, Masson, 1996.
3. Barthelemy C., Adrien J.L., Tanguay P., Garreau B., Fermanian J., Roux S., Sauvage D., Lelord G. The Behavioural Summarized Evaluation: validity and reliability of a scale of assessment of autistic behaviours. J. Aut. Dev. Disorders. 20:1990;189-204.
4. Barthelemy C., Adrien J.L., Roux S., Garreau B., Perrot A., Lelord G. Sensitivity and specificity of the Behavioural Summarized Evaluation (BSE) for the assessment of autistic behaviours. J. Aut. Dev. Disorders. 22:1992;23-31.
5. Bates E. The Emergence of Symbols: Cognition and Communication in Infancy. 1979;Academic Press, New York. Tradition and Adaptation from Institute of Child Neuropsychiatry, University of Milan, Italy, 1996.
6. Bouvard M.P., Leboyer M., Launay J.-M., Recasens C., Plumet M.-H., Waller-Perotte D., Tabuteau F., Bondoux D., Dugas M., Lensing P., Panksepp J. Low-dose Naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psych. Res. 58:1995;191-201.
7. Brambilla F., Guareschi-Cazzullo A., Tacchini C., Musetti C., Panerai A.E., Sacerdote P. β-Endorphin and cholecystokinin 8 concentrations in peripheral blood mononuclear cells of autistic children. Neuropsychobiology. 35:1997;1-4.
8. Buitelaar J.K., van Engeland H., De Kogel K.H., De Vries H., van Hoof J., van Ree J.M. The use of adrenocorticotrophic hormone (G-9) Analog ORG 2766 in autistic children. Effects on the organization of behaviour. Biol. Psychiatry. 31:1992;1119-1129.
9. Campbell M., Adams P., Small A., McVeigh-Tesch L., Curren E.L. Naltrexone in infantile autism. Psychopharmacol. Bull. 24:(1):1988;135-139.
10. Campbell M., Anderson L.T., Small A.M., Locascio J.J., Lynch N.S., Choroco M.C. Naltrexone in autistic children: a double-blind and placebo-controlled study. Psychopharmacol. Bull. 26:(1):1990;130-135.
11. Campbell M., Anderson L.T., Small A.M., Adams P., Gozalez N.M., Ernst M. Naltrexone in autistic children: behavioural symptoms and attentional learning. J. Am. Acad. Child Adolesc. Psychiatry. 32:(6):1993;1283-1291.
12. Campbell M., Shay J. The pervasive developmental disorders. Kaplan H.I., Sadock B.J., Comprehensive Textbook of Psychiatry/VI. 1994;Williams & Wilkins, Baltimore.
13. Chamberlain R.S., Herman B.H. A novel biochemical model linking dysfunctions in brain melatonin, proopiomelanocortin peptides, and serotonin in autism. Biol. Psychiatry. 28:1990;773-793.
14. Ernst M., Devi L., Silva R.R., Gonzales N.M., Small A.M., Malone R.P., Campbell M. Plasma β-endorphin levels, Naltrexone and haloperidol in autistic children. Psychopharmacol. Bull. 29:1993;221-227.
15. Gillberg C., Terenius L., Lönnerholm G. Endorphin activity in childhood psychosis: spinal fluid levels in 24 cases. Arch. Gen. Psychiatry. 42:1985;780-783.
16. Gillberg C., Terenius L., Hagberg B., Witt-Engerström I., Eriksson I. CSF β-endorphins in childhood neuropsychiatric disorders. Brain Dev. 12:1990;88-92.
17. Griffiths R. The Abilities of Babies: a Study in Mental Measurements. 1976;Association for Research in Infant and Child Development.
18. Herman B., Hammock K., Arthur-Smith A., Egan J., Chatoor I., Werner A., Zelnik N. Naltrexone decrease self-injurious behaviour. Ann. Neurol. 22:1987;550-552.
19. Herman B., Arthur-Smith A., Verebey K., Alrazi J., Hammock M.K. Effects of acute administration of Naltrexone on plasma concentrations of Naltrexone, 6-B-naltrexol, β-Endorphin and cortisol in children. Soc. Neurosci. Abstr. 14:1988;665.
20. Herman B., Hammock K., Arthur-Smith A., Kuehl K., Appelgate K. Effects of acute administration of Naltrexone on cardiovascular function, body temperature, body weight and serum concentrations of liver enzymes in autistic children. Dev. Pharmacol. Ther. 12:1989;118-127.
21. Herman B. Effects of opioid receptor antagonists in the treatment of autism and self-injurious behaviour. Ratey J.J., Mental Retardation: Pharmacotherapies. Progress in Psychiatry. 32:1991;107-137 American Psychiatric Press, Washington, DC.
22. Kalat J. Speculations on similarities between autism and opiate addiction. J. Autism Child Schizophr. 8:1978;477-479.
23. Kolmen B.K., Feldman H.M., Handen B.L., Janosky J.E. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study. J. Am. Acad. Child Adolesc. Psychiatry. 34:(2):1995;223-231.
24. Leboyer M., Bouvard M.P., Launay J.-M., Tabuteau F., Waller D., Dugas M., Kerdelhue B., Lensing P., Panksepp J. Brief report: a double-blind study of Naltrexone in infantile autism. J. Autism Dev. Dis. 22:(2):1992;309-319.
25. Leboyer M., Bouvard M.P., Recasens C., Philippe A., Guilloud-Bataille M., Bondoux D., Tabuteau F., Dugas M., Panksepp J., Launay J.M. Difference between plasma N- and C-terminally directed β-endorphin immunoreactivity in infantile autism. Am. J. Psychiatry. 151:(12):1994;1797-1801.
26. Lensing P., Klingler D., Lampl C., Leboyer M., Bouvard M.P., Plumet M.H., Panksepp J. Naltrexone open-trial with a 5-year-old boy: a social rebound reaction. Acta Paedopsychiatr. 55:1992;169-173.
27. Marchetti B., Scifo R., Batticane N., Scapagnini U. Immunological significance of opioid dysfunction in infantile autism. Brain Dysfunct. 3:1990;346-354.
28. Meyerson B. Comparison of the effects of β-endorphin and morphine on exploratory and sociosexual behaviour in the male rate. Eur. J. Pharmacol. 69:1981;453-463.
29. Nagamitsu S. CSF β-endorphin levels in pediatric neurologic disorders. Kureme Med. J. 40:(4):1993;233-241.
30. National Institute of Mental Health . Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol. Bull. 21:1985;4.
31. Niesnik R.J.M., van Ree J.M. Neuropeptides and social behaviour of rats tested in dyadic encounteis. Neuropeptides. 4:1984;483-496.
32. Niesnik R.J.M., van Ree J.M. Involvement of opioid and dopaminergic systems in isolation-induced pinning and social groomings of young rats. Neuropharmacology. 28:1989;411-418.
33. Ogawa N., Panerai A.E., Lee S., Fosbach G., Havliceck V., Friesen H. β-Endorphin concentrations in the brain of intact and hypophysectomized rats. Life Sci. 25:1979;317-329.
34. Panerai A.E., Martini A., Di Giulio A.M., Fraiolo F., Vegni C., Pardi G., Marini A., Mantegazza P. Plasma β-endorphin, β-lipotropin, and met-enkephalin concentrations during pregnancy in normal and drug addicted women and their newborn. J. Clin. Metab. Endocrinol. 57:1983;537-542.
35. Panksepp J. A neurochemical theory of autism. Trends Neurosci. 2:1979;174-177.
36. Panksepp J., Herman B.H., Vilberg T., Bishop P., DeEskenazi F.G. Endogenous opioids and social behaviour. Neurol. Biobehav. Rev. 4:1980;473-487.
37. Panksepp J., Sahley T. Possible brain opioid involvement in disrupted social intent and language development of autism. Schopler E., Mesibov G., Neurobiological Issues in Autism. 1987;Plenum, New York.
38. Panksepp J., Lensing P. Naltrexone treatment of autism: a synopsis of an open trial with four children. J. Autism Dev. Disorder. 21:1991;135-141.
39. Ross D.L., Klykylo W.M., Hitzeman R. Reduction of elevated CSF β-Endorphin by fenfluramine in infantile autism. Neurology. 3:1987;83-86.
40. Sacerdote P., Breda M., Barcellini W., Meroni P.L., Panerai A.E. Age related changes of β-endorphin and cholecystokinin in human and rat mononuclear cells. Peptides. 12:1991;1353-1356.
41. Sacerdote, P. (1998) Personal communication.
42. Sahley T.L., Panksepp J. Brain opioids and autism: an update analysis of possible linkages. J. Autism Dev. Dis. 17:1987;201-216.
43. Sandman C.A., Barron J.L., Chicz-DeMet A., Demet E.M. Brief report: plasma β-endorphin and cortisol levels in autistic patients. J. Autism Dev. Dis. 21:1991;83-87.
44. Walters A.S., Barret R.P., Feinstein C., Mercuriou A., Hole W.T. A case report of Naltrexone treatment of self-injury and social withdrawal in autism. J. Aut. Dev. Disorder. 20:1990;169-176.
45. Weizman R., Weizman A., Tyano S., Szekely G., Weissman B., Sarne Y. Humoral-β-endorphin blood levels in autistic, schizophrenic and healthy subjects. Psychopharmacology. 82:1984;368-370.
46. Willemsen-Swinkels S.H.N., Buitelaar J.K., Weijnen F.G., van Engeland H. Placebo-controlled acute dosage Naltrexone study in young autistic children. Psychiatry Res. 58:1995;203-215.
47. Zingarelli G., Ellman G., Hom A., Wymore M., Heidorn S., Chicz-DeMet A. Clinical effects of Naltrexone on autistic behaviour. Am. J. Ment. Retard. 97:1992;57-63.